

Threshold Pharmaceuticals

Investment summary: A new threshold

The TH-302 Phase III study in soft tissue sarcoma (STS) has been expanded to include another 170 patients. This reflects new assumptions about survival in the doxorubicin control arm and faster-than-expected enrolment, and maintains the trial power to detect a four-month survival benefit. Importantly, we expect a modest impact on trial timelines (three to six months) and expenditure (Merck KGaA contributes 70% of trial costs).

Expanded TH-302 Phase III trial in STS...

Threshold has amended the protocol of its ongoing TH-302 Phase III study in front-line STS, with the FDA agreeing to changes under the existing SPA agreement. The trial is evaluating TH-302 + doxorubicin vs doxorubicin alone in subjects with metastatic or locally advanced unresectable STS. The trial expansion to 620 patients (from 450) and elimination of an interim PFS analysis (mid-2013) relates to the higher overall survival (OS) benefit seen with doxorubicin in recent studies (12.8 months in EORTC 62012) and faster-than-expected recruitment.

...remains powered to show four-month OS benefit

The addition of 170 patients maintains the study's 85% power to detect a four-month increase in median OS for TH-302+dox (16 months) vs dox alone (12 months). With the OS analysis based on 434 events (previously 323), the enlarged sample size strengthens the trial's ability to detect a clinically meaningful (four-month) and statistically significant ($p < 0.05$) benefit for TH-302. Eliminating the interim PFS futility analysis makes sense in our view, given that the trial will be largely enrolled (around year-end 2013) by the time the analysis would be conducted and, moreover, an OS benefit is required for FDA approval.

Modest impact on trial timelines and cost

Importantly, we expect the STS trial expansion to have little impact on trial timelines (around a three- to six-month delay) and cost. On current projections, Threshold expects to undertake an interim OS analysis after 235 deaths in H114 (previously end-2013/early-2014) and final OS data in H115 (previously early-2015). Given that the interim analysis has a high statistical bar ($p < 0.0023$) for early termination, we believe the most likely outcome is trial continuation to final OS data.

Valuation: EV of \$212m

Despite the uptick in share price (c 11%) post the Phase III amendment, Threshold's EV of only \$212m suggests the market still underestimates the potential of TH-302 in STS and pancreatic cancer (also Phase III), and the Merck partnership (\$525m milestones, double-digit royalties and US co-promotion option).

Consensus estimates

Year End	Revenue (\$m)	PBT (\$m)	EPS (c)	DPS (c)	P/E (x)	Yield (%)
12/11	-	(25.7)	(0.6)	0.0	N/A	N/A
12/12	5.9	(71.1)	(1.3)	0.0	N/A	N/A
12/13e	12.6	(24.7)	(0.6)	0.0	N/A	N/A
12/14e	13.7	(29.7)	(0.5)	0.0	N/A	N/A

Source: Bloomberg

Pharma & biotech

3 July 2013

Price \$5.58
Market cap \$316m

Share price graph



Share details

Code	THLD
Listing	NASDAQ
Sector	Pharma & biotech
Shares in issue	56.6m

Business description

Threshold Pharmaceuticals is a US biotech company focused on oncology drugs targeting tumour hypoxia, the low-oxygen condition found in most solid tumours and some blood cancers. TH-302 is in Phase III trials for soft tissue sarcoma (STS) and pancreatic trials in multiple other cancers. TH-302 is partnered with Merck KGaA.

Bull

- TH-302 has blockbuster potential.
- Merck funds 70% of TH-302 development costs.
- Net cash of \$104m at end-Q113.

Bear

- Pancreatic cancer treatment landscape could change before 2015.
- TH-302 could fail to show survival benefit in STS Phase III study
- Single product risk.

Analysts

Dr Mike Aitkenhead	+44 (0)20 3077 5736
Robin Davison	+44 (0)20 3077 5737

healthcare@edisongroup.com

EDISON QUICKVIEWS ARE NORMALLY ONE OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Berlin, Sydney and Wellington. Edison is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is not regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com.

DISCLAIMER

Copyright 2013 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is not registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE [2013]. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.